CCCWFU 60307 - Pilot study to evaluate the anti-tumor effect of erlotnib administered befor surgery in operable patients with squamous cell carcinoma of the head and neck (HNSCC).
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 31 Jul 2017 Status changed from active, no longer recruiting to completed.
- 25 Jan 2013 Planned end date changed from 1 Mar 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov. (NCT01588613)